Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, pasireotide (Signifor®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed. |
||
|
||
Medicine details |
||
| Medicine name | pasireotide diaspartate (Signifor®) | |
| Formulation | 0.3 mg solution for injection, 0.6 mg solution for injection, 0.9 mg solution for injection | |
| Reference number | 642 | |
| Indication | For the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed. |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 09/11/2012 | |
| Date of issue | 13/11/2012 | |